Britain and America have finalized a key commercial pact that will keep zero import taxes on UK drug products entering the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to boost funding on medicines through the NHS. This commitment ensures that import taxes on these key products will stay at nothing for a timeframe of 36 months.
This development comes after recent threats to dramatically increase import taxes on branded pharmaceutical imports, with figures floated as high as double the cost.
"This arrangement between the UK reinforces the international landscape for innovative medicines and establishes long-overdue balance to American-British medicine commerce," a statement noted.
Economic Significance
Medicines are one of the Britain's largest export categories to the United States, which is easily the primary market for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure represented 17.4% of all goods exports in that timeframe.
"This guarantee secures employment, stimulates capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Specific British Pledges
The agreement involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be restricted at 15%. Previously, refunds were more than 20%.
Industry Background
This agreement follows a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
The disagreement were intensified by arguments that American consumers were paying a premium for the equivalent treatments than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
